Adtalem Global Education (NYSE:CVSA) Rating Lowered to Hold at Zacks Research

Key Points

• Adtalem Global Education was downgraded by Zacks Research from a "strong-buy" to a "hold"; overall analyst coverage shows two Buys and two Holds with an average rating of "Moderate Buy" and an average price target of $150.00.
• The company reported quarterly EPS of $2.43 on $503.39 million in revenue, with a net margin of 13.41% and ROE of 20.24%; the stock trades near $116 with a P/E of 17.09 and a 12‑month range of $86.97–$156.26.
• Insiders are buying: Director Michael W. Malafronte bought 8,890 shares at about $100.94, and insiders acquired 37,236 shares (~$3.75M) over the last 90 days, with insiders owning 2.50% of the company.

Adtalem Global Education (NYSE:CVSA - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Wednesday,Zacks.com reports.

CVSA has been the topic of a number of other research reports. Weiss Ratings assumed coverage on Adtalem Global Education in a report on Wednesday, February 25th. They issued a "hold (c+)" rating on the stock. Truist Financial started coverage on shares of Adtalem Global Education in a report on Tuesday. They set a "buy" rating and a $130.00 target price for the company. Finally, Barrington Research reiterated an "outperform" rating and set a $170.00 price target on shares of Adtalem Global Education in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Adtalem Global Education has an average rating of "Moderate Buy" and an average price target of $150.00.

Adtalem Global Education Price Performance

CVSA opened at $116.39 on Wednesday. The company has a market cap of $4.02 billion, a PE ratio of 17.09, a P/E/G ratio of 0.98 and a beta of 0.72. Adtalem Global Education has a twelve month low of $86.97 and a twelve month high of $156.26. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.68.

Adtalem Global Education (NYSE:CVSA - Get Free Report) last issued its earnings results on Wednesday, January 28th. The company reported $2.43 earnings per share (EPS) for the quarter. The company had revenue of $503.39 million for the quarter. Adtalem Global Education had a net margin of 13.41% and a return on equity of 20.24%.

Insider Transactions at Adtalem Global Education

In other news, Director Michael W. Malafronte bought 8,890 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were bought at an average price of $100.94 per share, for a total transaction of $897,356.60. Following the purchase, the director owned 25,395 shares in the company, valued at approximately $2,563,371.30. The trade was a 53.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 37,236 shares of company stock valued at $3,752,866. Corporate insiders own 2.50% of the company's stock.

About Adtalem Global Education

Adtalem Global Education NYSE: CVSA is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.